PubMed HealthSearch

PubMed · 2688560

[Prostatic cancer].

Abstract

The incidence of prostatic cancer has been increasing and will probably increase more in Japan in the future, although it may not be probable that the incidence become high as in the western countries. Carcinoma of the prostate gland is one of cancers in which main treatment modality is hormonal manipulation. It is evident through epidemiological study that the development of prostatic cancer is associated with environmental factors such as dietary or sexual life styles which may influence on the hormonal milieu. In animal models aging and androgens are indispensable factors when inducing prostatic cancer. Thus the mechanism of hormone dependency in prostatic cancer should be elucidated to consolidate the basis of its hormonal therapy. It is shown in in vivo or in vitro experiments that the hormonal action is mediated by several growth factors. However, this must be investigated when androgens or growth factors play their roles during the process of carcinogenesis. While the main therapy of prostatic cancer is hormonal it is generally accepted that a radical means to treat prostatic cancer is solely total excision of the prostate gland when cancer is confined to the prostate. Hormone therapy is conservative principally, but is only available means now for treating patients with advanced prostatic cancer. In order to obtain more effective hormonal manipulation, the mechanism of hormone dependency must be understood. We need more effective antiandrogenic agents with lesser adverse effects. The final goal in the treatment of prostatic cancer is in its eradication. Therefore, it is urgently necessary to establish multidisciplinary treatment which includes surgery, hormonal manipulation, chemotherapy, radiation and immunotherapy for the eradication of advanced prostatic cancer.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

O Yoshida, K Oishi, Y Arai, H Mori. 1989. [Prostatic cancer].. https://pubmed.ncbi.nlm.nih.gov/2688560/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[The anti-androgen flutamide in the treatment of prostatic hyperplasia].

The authors treated 23 benign prostatic hyperplasia (BPH) patients with antiandrogen flutamide. Half of the patients were treated with 500 mg, the another part with 750 mg flutamide for three months, and after 3 months brake again for 3 months. The decrease of the residual urine and an increase of the flow were observed. The subjective parameters were improved, too. In some patients side effects (gynecomastia, loss of appetite and potency) were observed. There was no different in the effect of the two doses.

Androgen Antagonists

Recent developments in endocrine treatment of prostate cancer.

Cancer of the prostate gland is the most frequently occurring malignant lesion in men. Because most prostate cells depend on androgen for growth, removal of testosterone by either orchiectomy or medical castration using diethylstilbestrol or a luteinizing hormone-releasing hormone (LHRH) analogue is first-line treatment for patients with symptomatic Stage D2 disease. The trend in hormonal therapy has been toward long-acting minimal-dosing high-compliance regimens, capitalizing on the recent availability of the long-acting LHRH analogues, which require only monthly injections to maintain castration levels of testosterone, and the nonsteroidal antiandrogen ICI 176,334, which (in early clinical trials) appears to block intracellular testosterone activity with a once-a-day oral regimen. To eliminate the rapid LH increase that can occur during early agonist therapy, combinations of LHRH analogues and antiandrogens (total androgen blockade) have been tested and appear promising. The effects of hormonal treatment in patients with symptomatic Stage D2 prostate cancer have been studied extensively and are relatively well understood. By contrast, hormonal treatment has not been explored in contemporary randomized Phase III trials of asymptomatic Stage D2, D1, or C disease, localized Stage B or A disease, or before prostate surgery or radiation treatment. Research must continue to determine the optimal regimen that suppresses testosterone activity with the least amount of toxicity.

Androgen Antagonists

Distant disease.

Explore the source record for details and available documents.

Androgen Antagonists